Published in Br J Cancer on December 18, 2007
High Ki67, Bax, and thymidylate synthase expression well correlates with response to chemoradiation therapy in locally advanced rectal cancers: proposal of a logistic model for prediction. Br J Cancer (2009) 1.08
Predicting the response to preoperative radiation or chemoradiation by a microarray analysis of the gene expression profiles in rectal cancer. Surg Today (2012) 1.02
P53 status as a predictive biomarker for patients receiving neoadjuvant radiation-based treatment: a meta-analysis in rectal cancer. PLoS One (2012) 0.96
Thymidylate synthase genotype-directed neoadjuvant chemoradiation for patients with rectal adenocarcinoma. J Clin Oncol (2011) 0.94
Expression of Transketolase like gene 1 (TKTL1) predicts disease-free survival in patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy. BMC Cancer (2011) 0.93
Molecular targeted treatment and radiation therapy for rectal cancer. Strahlenther Onkol (2009) 0.92
Predictive factors of the response of rectal cancer to neoadjuvant radiochemotherapy. Cancers (Basel) (2011) 0.83
Thymidylate synthase germline polymorphisms in rectal cancer patients treated with neoadjuvant chemoradiotherapy based on 5-fluorouracil. J Cancer Res Clin Oncol (2010) 0.83
Role of tumor size in the pre-operative management of rectal cancer patients. BMC Gastroenterol (2010) 0.81
New Perspectives on Predictive Biomarkers of Tumor Response and Their Clinical Application in Preoperative Chemoradiation Therapy for Rectal Cancer. Yonsei Med J (2015) 0.80
Microsatellite instability predicts clinical outcome in radiation-treated endometrioid endometrial cancer. Int J Radiat Oncol Biol Phys (2010) 0.78
Association of beclin 1 expression with response to neoadjuvant chemoradiation therapy in patients with locally advanced rectal carcinoma. Int J Cancer (2015) 0.78
Microsatellite instability and ploidy status define three categories with distinctive prognostic impact in endometrioid endometrial cancer. Oncotarget (2014) 0.78
Thymidylate synthase as a prognostic biomarker for locally advanced rectal cancer after multimodal treatment. Ann Surg Oncol (2011) 0.77
Predictive value of APAF-1 and COX-2 expression in pathologic complete response to neoadjuvant chemoradiotherapy for patients with locally advanced rectal adenocarcinoma. Oncotarget (2016) 0.75
Delimiting Allelic Imbalance of TYMS by Allele-Specific Analysis. Medicine (Baltimore) (2015) 0.75
Time to Redefine the Role of Routine Combined-Modality Therapy for Invasive Stage-II/III Rectal Cancer? Gastrointest Cancer Res (2009) 0.75
Prognosis and value of preoperative radiotherapy in locally advanced rectal signet-ring cell carcinoma. Sci Rep (2017) 0.75
Predictive markers of chemoradiotherapy for rectal cancer: comparison of biopsy specimens taken before and about 1 week after the start of chemoradiotherapy. Int J Clin Oncol (2015) 0.75
Predictive clinical model of tumor response after chemoradiation in rectal cancer. Oncotarget (2017) 0.75
Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med (2004) 25.68
Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial. N Engl J Med (1997) 9.99
Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. J Clin Oncol (2006) 3.24
Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol (2004) 2.95
Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. J Clin Oncol (2002) 2.28
Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol (1997) 2.19
A phase I-II study of weekly oxaliplatin, 5-fluorouracil continuous infusion and preoperative radiotherapy in locally advanced rectal cancer. Ann Oncol (2005) 2.09
The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol (1994) 1.94
Fluorouracil in colorectal cancer--a tale of two drugs: implications for biochemical modulation. J Clin Oncol (1997) 1.76
Long-term prognostic significance of extent of rectal cancer response to preoperative radiation and chemotherapy. Ann Surg (2002) 1.66
Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy. J Clin Oncol (2006) 1.57
Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines. Cancer Res (1992) 1.50
Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer. J Clin Oncol (2002) 1.22
Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. J Clin Oncol (1999) 1.12
Thymidylate synthase protein expression in advanced colon cancer: correlation with the site of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil. Clin Cancer Res (1999) 1.12
Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites. J Clin Oncol (2003) 1.08
Relation between thymidylate synthase expression and survival in colon carcinoma, and determination of appropriate application of 5-fluorouracil by immunohistochemical method. Ann Surg Oncol (2000) 1.03
Microsatellite status and cell cycle associated markers in rectal cancer patients undergoing a combined regimen of 5-FU and CPT-11 chemotherapy and radiotherapy. Anticancer Res (2004) 1.00
Characterization of a thymidylate synthase (TS)-inducible cell line: a model system for studying sensitivity to TS- and non-TS-targeted chemotherapies. Clin Cancer Res (2001) 0.98
A new prognostic factor for colorectal carcinoma, thymidylate synthase, and its therapeutic significance. Cancer (1998) 0.97
VEGF as a predictive marker of rectal tumor response to preoperative radiotherapy. Cancer (2005) 0.95
Down-regulation of thymidylate synthase expression and its steady-state mRNA by oxaliplatin in colon cancer cells. Anticancer Drugs (2004) 0.89
Tumor response to neoadjuvant chemoradiation therapy for rectal adenocarcinoma is mediated by p53-dependent and caspase 8-dependent apoptotic pathways. Clin Colorectal Cancer (2005) 0.86
A predictive model of rectal tumor response to preoperative radiotherapy using classification and regression tree methods. Clin Cancer Res (2005) 0.86
Evaluating the combination of molecular prognostic factors in tumor radiosensitivity in rectal cancer. Hepatogastroenterology (2005) 0.85
Primary colorectal tumour is not an accurate predictor of thymidylate synthase in lymph node metastasis. Oncol Rep (2002) 0.83
Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab (2001) 6.12
Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol (2008) 4.27
JC-1, but not DiOC6(3) or rhodamine 123, is a reliable fluorescent probe to assess delta psi changes in intact cells: implications for studies on mitochondrial functionality during apoptosis. FEBS Lett (1997) 3.41
Measuring fast neutrons in Hiroshima at distances relevant to atomic-bomb survivors. Nature (2003) 2.97
Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior. World J Surg (1996) 2.69
The complete sequence of a full length cDNA for human liver glyceraldehyde-3-phosphate dehydrogenase: evidence for multiple mRNA species. Nucleic Acids Res (1984) 2.57
The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO). Ann Oncol (2013) 2.53
Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann Oncol (2004) 2.27
Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol (2006) 2.19
Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol (2002) 2.14
Histopathological classification of nonantral gastric endocrine growths in man. Digestion (1988) 1.85
Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study. Ann Oncol (2012) 1.78
Better red than dead: carotenoid-based mouth coloration reveals infection in barn swallow nestlings. Proc Biol Sci (2000) 1.75
EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations. Lung Cancer (2010) 1.74
ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: prognostic evaluation by pathological analysis. Gastroenterology (1999) 1.66
Amoxicillin-clavulanic acid in treatment of urinary tract infection due to gram-negative bacteria resistant to penicillin. Antimicrob Agents Chemother (1981) 1.61
Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol (1997) 1.54
Role of recombinant interferon-gamma maintenance in responding patients with small cell lung cancer. A randomised phase III study of the EORTC Lung Cancer Cooperative Group. Eur J Cancer (1997) 1.52
Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients. Br J Cancer (2012) 1.50
Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma. Ann Oncol (2005) 1.49
Anorectal malformations and neurospinal dysraphism: is this association a major risk for continence? Pediatr Surg Int (2010) 1.46
Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). Br J Cancer (2009) 1.46
The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006. Ann Oncol (2007) 1.44
Disodium cromoglycate versus diet in the treatment and prevention of nickel-positive pompholyx. Contact Dermatitis (1990) 1.42
Dual therapy with high or low doses of omeprazole does not achieve an acceptable rate of Helicobacter pylori eradication in duodenal ulcer patients. A multicentre randomized long-term detailed study. Ital J Gastroenterol Hepatol (1997) 1.40
Mycobacteria and other environmental organisms as immunomodulators for immunoregulatory disorders. Springer Semin Immunopathol (2003) 1.40
[Paraneoplastic syndromes: a review]. Clin Ter (2006) 1.39
Circulating immune complexes and rheumatoid factor in schistosomiasis and visceral leishmaniasis. Am J Trop Med Hyg (1983) 1.38
[Who needs a gastroenterology pathologist?]. Pathologica (1996) 1.38
Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes' B colorectal cancer patients: how much evidence is enough? Ann Oncol (2003) 1.36
Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma. Br J Cancer (2011) 1.34
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? Ann Oncol (2012) 1.28
Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol (1996) 1.27
Serodiagnosis of infectious diseases with antigen microarrays. J Appl Microbiol (2004) 1.25
VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib. Br J Cancer (2012) 1.21
Managing patients with lung cancer. Common international guidelines must be developed. BMJ (2000) 1.20
Insulin-like growth factor (IGF) 1 and 2 help to predict disease outcome in GIST patients. Ann Oncol (2008) 1.19
Maternal antibodies but not carotenoids in barn swallow eggs covary with embryo sex. J Evol Biol (2003) 1.17
Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel. Ann Oncol (2004) 1.17
Ghrelin protects against ethanol-induced gastric ulcers in rats: studies on the mechanisms of action. Endocrinology (2003) 1.16
Comparative evaluation of the effects of indomethacin and ibuprofen on cerebral perfusion and oxygenation in preterm infants with patent ductus arteriosus. J Pediatr (1997) 1.16
Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma. Br J Cancer (2013) 1.15
Expression and function of the insulin-like growth factor I system in human non-small-cell lung cancer and normal lung cell lines. Int J Cancer (1994) 1.15
A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer. Ann Oncol (2000) 1.13
Nephrotic syndrome in patients with Schistosoma mansoni infection. Am J Trop Med Hyg (1973) 1.13
Renal involvement in visceral leishmaniasis. Am J Kidney Dis (1985) 1.10
Validation of a novel diagnostic standard in HPV-positive oropharyngeal squamous cell carcinoma. Br J Cancer (2013) 1.10
ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin. Br J Cancer (2013) 1.10
Gene expression profiles of progressive pancreatic endocrine tumours and their liver metastases reveal potential novel markers and therapeutic targets. Endocr Relat Cancer (2006) 1.10
Gastric endocrine cell proliferation. Association with Zollinger-Ellison syndrome. Arch Pathol (1974) 1.09
Ampullary adenocarcinoma in neurofibromatosis type 1. Case report and literature review. Mod Pathol (2001) 1.09
Gastroenteropancreatic (neuro)endocrine neoplasms: the histology report. Dig Liver Dis (2011) 1.09
Terminally differentiated astrocytes lack DNA damage response signaling and are radioresistant but retain DNA repair proficiency. Cell Death Differ (2011) 1.08
Cure of Helicobacter pylori infection in atrophic body gastritis patients does not improve mucosal atrophy but reduces hypergastrinemia and its related effects on body ECL-cell hyperplasia. Aliment Pharmacol Ther (2000) 1.07
Cytomegalovirus infection after autologous stem cell transplantation: incidence and outcome in a group of patients undergoing a surveillance program. Transpl Infect Dis (2006) 1.07
FK506 binding protein 51 positively regulates melanoma stemness and metastatic potential. Cell Death Dis (2013) 1.06
Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients. Ann Oncol (2007) 1.06
Complete spontaneous remission of non-small-cell lung cancer: a case report. Lung Cancer (2004) 1.06
Establishment of four new mesothelioma cell lines: characterization by ultrastructural and immunophenotypic analysis. Eur Respir J (1999) 1.05
Pazopanib and sunitinib trigger autophagic and non-autophagic death of bladder tumour cells. Br J Cancer (2013) 1.05
Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients. Br J Cancer (2011) 1.04
Combined analysis of E-cadherin gene (CDH1) promoter hypermethylation and E-cadherin protein expression in patients with gastric cancer: implications for treatment with demethylating drugs. Ann Oncol (2004) 1.04
Pharmacology of cefaclor in normal volunteers and patients with renal failure. Antimicrob Agents Chemother (1978) 1.04
Classification of gastric neuroendocrine tumors and its clinicopathologic significance. World J Gastroenterol (1998) 1.03
Composite carcinoid-adenocarcinoma of the stomach associated with multiple gastric carcinoids and nonantral gastric atrophy. Cancer (1989) 1.03
Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study. Ann Oncol (2009) 1.02
Reversal of long-standing iron deficiency anaemia after eradication of Helicobacter pylori infection. Scand J Gastroenterol (1997) 1.02
Two-thirds of atrophic body gastritis patients have evidence of Helicobacter pylori infection. Helicobacter (2001) 1.01
Role of Helicobacter pylori infection in pernicious anaemia. Dig Liver Dis (2000) 1.01
KIT and PDGFRalpha mutations in 104 patients with gastrointestinal stromal tumors (GISTs): a population-based study. Ann Oncol (2008) 1.01
Heterotopic mesenteric ossification ('intraabdominal myositis ossificans'): report of five cases. Am J Surg Pathol (1999) 1.00
Atrophic body gastritis patients with enterochromaffin-like cell dysplasia are at increased risk for the development of type I gastric carcinoid. Eur J Gastroenterol Hepatol (2001) 1.00
The Italian version of the Functional Disability Index of the Health Assessment Questionnaire. A reliable instrument for multicenter studies on rheumatoid arthritis. Clin Exp Rheumatol (1993) 1.00
Letter: ECL cell proliferation and gastrin levels. Gastroenterology (1975) 1.00
Influence of age, gender, hormonal status and smoking habits on colonic transit time. Neurogastroenterol Motil (1995) 0.99
Systematic bias in the reporting of angioplasty outcomes: accuracy of visual estimates of absolute lumen diameters. Can J Cardiol (1994) 0.99
PTEN status in advanced colorectal cancer treated with cetuximab. Br J Cancer (2009) 0.99
RASSF1A promoter methylation and 3p21.3 loss of heterozygosity are features of foregut, but not midgut and hindgut, malignant endocrine tumours. J Pathol (2005) 0.99
Risk factors for progression to gastric neoplastic lesions in patients with atrophic gastritis. Aliment Pharmacol Ther (2010) 0.98
Cutaneous seeding after ultrasound-guided percutaneous ethanol injection for treatment of hepatocellular carcinoma. J Clin Ultrasound (2001) 0.98
Atrophic body gastritis: distinct features associated with Helicobacter pylori infection. Helicobacter (1997) 0.98
High prevalence of atrophic body gastritis in patients with unexplained microcytic and macrocytic anemia: a prospective screening study. Am J Gastroenterol (1999) 0.98
Neuroendoscopic management of posterior third ventricle and pineal region tumors: technique, limitation, and possible complication avoidance. Neurosurg Rev (2012) 0.97
Interleukin 1B gene (IL-1B) and interleukin 1 receptor antagonist gene (IL-1RN) polymorphisms in Helicobacter pylori-negative gastric cancer of intestinal and diffuse histotype. Ann Oncol (2005) 0.97
[Age- and sex-specific standard values of colonic transit time in healthy subjects]. Schweiz Med Wochenschr (1992) 0.97
Central ghrelin gastroprotection involves nitric oxide/prostaglandin cross-talk. Br J Pharmacol (2008) 0.97
Novel therapeutic approaches to cancer patients with bone metastasis. Crit Rev Oncol Hematol (2001) 0.97